We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

MALDI-TOF-MS Evaluated for Rapid Diagnosis of Bacteremia and Fungemia

By LabMedica International staff writers
Posted on 13 Jan 2021
Print article
Image: The Microflex LT MALDI-TOF mass spectrometer and Rapid Sepsityper kit for the identification of pathogenic organisms (Photo courtesy of Bruker Daltonics).
Image: The Microflex LT MALDI-TOF mass spectrometer and Rapid Sepsityper kit for the identification of pathogenic organisms (Photo courtesy of Bruker Daltonics).
When sepsis occurs, it is essential to begin an effective and potent antibacterial or antifungal treatment as soon as possible as early administration and achievement of microbicidal concentrations are associated with better survival in community-acquired and hospital-acquired septicemia.

Rapid species identification is now possible by several techniques directly from positive blood cultures. It allows a first quick adaptation of empirical treatment if inappropriate, according to the species identified. However, available techniques are either expensive such as multiplex polymerase chain reaction (PCR) or fluorescence in situ hybridization using peptide nucleic acid probes (PNA-FISH), that are delayed by a first 4 to 8 hours subculture on agar medium or are time-consuming.

Medical Microbiologists at the Université Grenoble Alpes (Grenoble, France) analyzed 379 positive blood cultures bottles and all the blood cultures were incubated in a BD BACTEC FX instrument (Becton Dickinson, Franklin Lakes, NJ, USA). Among those, 299 samples were selected as they corresponded to the first positive blood culture bottle for all new episodes of bacteremia during random days. Fifty-one positive blood cultures bottles were also included in the study in order to compare identification rates obtained on aerobic or anaerobic bottles for facultative anaerobes (27 second positive bottle of a pair of blood culture already included and 12 additional pairs of positive blood culture).

Matrix Assisted Laser Desorption Ionization—Time of Flight Mass Spectrometry (MALDI-TOF-MS) identification was performed using either the Rapid protocol (10 minutes turnaround time) of the Sepsityper kit (Bruker Daltonics, Bremen, Germany) or the Standard procedure (30 minutes turnaround time). MALDI‑TOF-MS data analysis and evaluation of performance were all acquired on a Bruker Daltonics’ Microflex LT MALDI-TOF mass spectrometer. To provide an optimized diagnosis strategy the team also evaluated the benefit of using an on-plate formic acid extraction step and compared identification rates depending on the type of positive blood culture bottles (aerobic or anaerobic) for facultative anaerobes.

The investigators reported that identification rates were determined prospectively on 350 bacterial and 29 fungal positive blood cultures, and compared to conventional diagnostic method. Their rapid diagnosis strategy (Rapid Sepsityper protocol: one spot with and one without formic acid extraction step) combined to MBT-Sepsityper module provided 65.4%, 78.9% and 62% reliable identification to the species level of monomicrobial positive blood cultures growing respectively Gram-positive, Gram-negative bacteria or yeast.

Importantly, identification rates of Gram-positive bacteria were higher in anaerobic than in aerobic bottles (77.8% versus 22.2%), if formic acid extraction step was performed (60.8% versus 39.2%) and if specific MBT-Sepsityper module was used (76.2% versus 61.9%), while no significant differences were observed for Gram-negative bacteria. For yeasts identification, formic acid extraction step improved rapid identification rate by 37.9% while the specific MBT-Sepsityper module increased overall performances by 38%, providing up to 89.7% reliable identification if associated with the standard Sepsityper protocol.

The authors concluded that the rapid Sepsityper protocol is an interesting commercial assay for quick bacterial identification in bloodstream infections (BSI) that could allow early adaptation of empirical antibiotic treatment according to the species identified. The study was published on December 9, 2020 in the journal Annals of Clinical Microbiology and Antimicrobials.

Related Links:
Université Grenoble Alpes
Becton Dickinson
Bruker Daltonics



New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.